Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPartners Grp E Regulatory News (PEY)

Share Price Information for Partners Grp E (PEY)

Share Price is delayed by 15 minutes
Get Live Data
9.04    0.00 (0.00%)
Bid:
8.68
Ask:
9.10
Spread: 0.42 (4.839%)
Market Cap: €612.09m
PEY Live PriceLast checked at - London Stock Exchange

Intraday Partners Grp E Share Chart

Stable performance in July

25 Aug 2016 07:00

RNS Number : 0734I
Princess Private Equity Holding Ltd
25 August 2016
 

News Release

Guernsey, 25 August 2016

 

Stable performance in July

 

· Princess Private Equity Holding Limited's ("Princess") net asset value ("NAV") stands at EUR 9.78 per share

· Overall portfolio developments (+0.3%) were positive while currency movements (-0.1%) were slightly negative

· Princess received distributions of EUR 5.0 million from exited investments and invested EUR 13.2 million

 

Distributions during the month came predominantly from Princess' legacy third party fund portfolio (EUR 2.5 million). Princess also received proceeds of EUR 1.3 million following the realization of US-based semiconductor manufacturer Freescale Semiconductor. Partners Group first invested in Freescale as part of a consortium in 2006, but the company experienced a significant decline in orders during the financial crisis which required it to reduce its cost base. Freescale subsequently held its IPO in 2011, raising the necessary capital to restructure its debt and held a secondary offering in 2014. The company was acquired by Dutch competitor NXP Semiconductors in a cash-and-stock transaction in December 2015, which valued the combined enterprise at over USD 40 billion. Princess received the cash proceeds from the transaction in April this year and subsequently sold the stock component in July.

 

Princess invested a total of EUR 13.2 million during the month, of which EUR 11.6 million was allocated to PCI Pharma Services (PCI). Partners Group acquired the global pharmaceutical services provider from selling private equity firm Frazier Healthcare Partners. Headquartered in Philadelphia, USA, PCI offers outsourced services across the entire pharmaceutical supply chain, including drug development and manufacturing, clinical trials and packaging services. The company has a diverse customer base of more than 350 companies, including the world's leading pharmaceutical manufacturers. PCI employs more than 2'800 people across the US and Europe, and generated sales of over USD 475 million in 2015. Following the acquisition, Partners Group plans to work closely with PCI's management team to add more specialized offerings to the product range and expand the company, both organically and through complementary add-on acquisitions.

 

On 18 August Princess held a conference call to update investors on the company's performance and the development of its portfolio during the second quarter of 2016. The presentation and replay facility are now available on the company's website:

 

http://princess-privateequity.net/en/investor_relations/web_cast_live-events.php.

 

 

Further information is available in the monthly report which can be accessed via:

http://www.princess-privateequity.net/financialreports.

 

Ends.

 

About Princess

Princess is an investment holding company founded in 1999 and domiciled in Guernsey. It invests, inter alia, in private equity and private debt investments. Princess is advised in its investment activities by Partners Group, a global private markets investment management firm with over EUR 49 billion in investment programs under management in private equity, private debt, private real estate and private infrastructure. Princess aims to provide shareholders with long-term capital growth and an attractive dividend yield. Princess is traded on the London Stock Exchange (ticker symbol: PEY). Further information: www.princess-privateequity.net.

 

Contacts

Princess Private Equity Holding Limited:

princess@princess-privateequity.net

www.princess-privateequity.net

 

Registered Number: 35241

 

Investor relations contact

George Crowe

Phone: +44 (0)20 7575 2771

Email: george.crowe@partnersgroup.com

 

Media relations contact

Partners Group

Jenny Blinch

Phone: +41 41 784 65 26

Email: jenny.blinch@partnersgroup.com

www.partnersgroup.com

 

This document does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities and neither is it intended to be an investment advertisement or sales instrument of Princess. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes must inform themselves about, and observe any such restrictions on the distribution of this document. In particular, this document and the information contained therein are not for distribution or publication, neither directly nor indirectly, in or into the United States of America, Canada, Australia or Japan.

 

This document may have been prepared using financial information contained in the books and records of the product described herein as of the reporting date. This information is believed to be accurate but has not been audited by any third party. This document may describe past performance, which may not be indicative of future results. No liability is accepted for any actions taken on the basis of the information provided in this document. Neither the contents of Princess' website nor the contents of any website accessible from hyperlinks on Princess' website (or any other website) is incorporated into, or forms part of, this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRBLGDIBXDBGLS
Date   Source Headline
27th May 20267:00 amRNSPGPE Ltd results presentation webcast details
18th May 20267:00 amRNSSave the date for Q1 2026 results announcement
7th May 20267:00 amRNSPGPE Ltd publishes March NAV
5th May 20267:00 amRNSDividend Declaration
1st May 20267:00 amRNSTransaction in Own Shares
30th Apr 20267:00 amRNSNotice of Annual General Meeting
14th Apr 20267:00 amRNSPGPE Ltd publishes February NAV
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSBuyback update
7th Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSAnnual results and webcast details
16th Mar 20267:00 amRNSSave the date for 2025 annual results announcement
16th Mar 20267:00 amRNSPGPE Ltd publishes January NAV
16th Mar 20267:00 amRNSSave the date for 2025 annual results announcement
16th Mar 20267:00 amRNSPGPE Ltd publishes January NAV
25th Feb 20267:00 amRNSTransaction in Own Shares
16th Feb 20267:00 amRNSPGPE Ltd publishes December NAV
12th Feb 20264:51 pmRNSHolding(s) in Company
12th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
30th Jan 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:01 amRNSBuyback update
28th Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSFree Cash Flow as at 31 December 2025
8th Jan 20267:04 amRNSPGPE Ltd publishes November NAV
24th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSNAV increased by 0.5% in October
10th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSDirector/PDMR Shareholding
27th Nov 20257:05 amRNSSale of Convex Group
27th Nov 20257:00 amRNSEsentia lists on Mexican Stock Exchange
26th Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSResults presentation webcast details
20th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20257:00 amRNSCredit facility renewed early
12th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSDividend Declaration
4th Nov 20257:00 amRNSNAV increased by 2.1% in September
4th Nov 20257:00 amRNSSave the date for Q3 2025 results announcement
3rd Nov 20257:00 amRNSSale of Clario
30th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.